About Agalimmune
Agalimmune is a Healthcare company based in London (United Kingdom) founded in 2013, and was acquired by BioLineRx in March 2017. Synthetic alpha-Gal immunotherapy is developed for solid tumors. The company has 4 employees. The company was acqui-hired. Agalimmune offers products and services including APHEXDA and Therapeutics Pipeline. Its focus areas include Life Sciences, Immunotherapy, Diversified and Oncology. Its legal entity is AGALIMMUNE LTD.
Company details
Agalimmune was founded in 2013 in London, United Kingdom, as a biopharma company focused on anti-cancer immunotherapy for solid tumors. The lead candidate, AGI-134, a synthetic alpha-Gal molecule, was developed to leverage pre-existing anti-alpha-Gal antibodies for inducing tumor cell cytotoxicity and adaptive immune responses. Intellectual property was licensed from the University of Massachusetts and KODE Biotech. The company was acquired by BiolineRx in 2017.
- Headquarters London, United Kingdom
- Employees 4
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website agalimmune.com
- Social LinkedIn X
- Acquired by BioLineRx (Mar 2017)
- Legal Name Agalimmune Ltd.
- Date of Incorporation 25 Apr, 2013
- Jurisdiction LONDON, UNITED KINGDOM
Products & Services of Agalimmune
Agalimmune offers a comprehensive portfolio of products and services, including APHEXDA and Therapeutics Pipeline.
FDA-approved treatment for specific cancers or rare diseases.
Portfolio of therapies for cancers and rare diseases therapies.
Investors in Agalimmune
Agalimmune has secured backing from 1 investor. Prominent investors backing the company include BioLineRx.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Clinical stage biopharmaceutical development company | 2003 | biolinerx.com |
Investor details for Agalimmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Agalimmune
2 dated milestones of Agalimmune across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Agalimmune is founded.
- Exit Acquired by BioLineRx.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Agalimmune
Agalimmune was founded in 2013.
Agalimmune is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Agalimmune has 4 employees.
Agalimmune was founded in 2013 in London, United Kingdom, as a biopharma company focused on anti-cancer immunotherapy for solid tumors. The lead candidate, AGI-134, a synthetic alpha-Gal molecule, was developed to leverage pre-existing anti-alpha-Gal antibodies for inducing tumor cell cytotoxicity and adaptive immune responses. Intellectual property was licensed from the University of Massachusetts and KODE Biotech. The company was acquired by BiolineRx in 2017.
Agalimmune offers APHEXDA and Therapeutics Pipeline.
Agalimmune has 1 investor. Key investors include BioLineRx.
Agalimmune operates through Agalimmune Ltd..
Yes. Agalimmune was acquired by BioLineRx in March 2017.
